B+
Bull case
25%
Probability
Target price
$10.50
+71.3% vs current
VNDA
VandaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$6.90
+12.6% vs current
B-
Bear case
30%
Probability
Target price
$4.25
-30.7% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+63.3
Score
AI commentary
As of May 9, 2026, the immediate market reaction was negative: VNDA closed at $7.39 on May 5, 2026, rose to $7.44 on the May 6 earnings day, then fell to $6.39 on May 7, 2026, a roughly 14% drop from the pre-print close. That suggests investors focused more on the revenue miss/wider loss and commercialization spend than on the raised guide. Trusted post-print analyst revision evidence remains thin in the packet, and analyst target-count visibility is unavailable, so this remains a cautious monitoring setup rather than a clean post-earnings re-rating call.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06catalystRaised 2026 guide now has to be proven by early NEREUS and Fanapt executionHigh impact
Vanda's May 6 earnings release raised full-year 2026 revenue guidance to $240-$290 million, including $10-$30 million from newly launched NEREUS, while Fanapt sales grew 26% year over year; the next few months of launch and prescription evidence will determine whether that guide raise is durable enough to outweigh HETLIOZ erosion and heavier commercial spend [#8-K-2026-05-06].
2026-12-12eventImsidolimab FDA action date remains the clearest binary upside/downside eventHigh impact
Vanda said the FDA accepted the imsidolimab BLA for generalized pustular psoriasis with a PDUFA target action date of December 12, 2026; approval would materially improve the late-2026 narrative, while a delay or negative outcome would likely pressure the shares further [#8-K-2026-05-06].
2026-12-31catalystMultiple late-stage readouts could reshape the pipeline view into late 2026 and early 2027High impact
Management said late-stage studies are expected to generate topline results in 2026 or early 2027, including Thetis for NEREUS in GLP-1-related vomiting, VQW-765 in social anxiety disorder by the end of 2026, and adjunctive BYSANTI in MDD in Q1 2027; these add optionality but remain timing- and execution-sensitive [#8-K-2026-05-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology